[Skip navigation]FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
 HHS Logo links to Department of Health and Human Services website
Drugs at FDA: FDA Approved Drug Products. Links to Initial Search Page FAQ  |  Instructions  |  Glossary  |  Contact Us  |  CDER Home 
Start Over (Drugs@FDA Home)

Drug Details
Drug Name(s) TRILEPTAL (Brand Name Drug)
FDA Application No. (NDA) 021014
Active Ingredient(s) OXCARBAZEPINE
Company NOVARTIS
Original Approval or Tentative Approval Date January 14, 2000
Chemical Type 1  New molecular entity (NME)
Review Classification S  Standard review drug  


Products on Application (NDA) #021014
    Click on a column header to re-sort the table:

Drug Name
Active Ingredients
Strength
Dosage Form/Route
Marketing
Status
RLD
TE
Code
TRILEPTAL  OXCARBAZEPINE  150MG  TABLET; ORAL  Prescription  No AB  
TRILEPTAL  OXCARBAZEPINE  300MG  TABLET; ORAL  Prescription  No AB  
TRILEPTAL  OXCARBAZEPINE  600MG  TABLET; ORAL  Prescription  Yes AB  

Back to Top | Back to Previous Page | Back to Drugs@FDA Home

Disclaimer
CDER Home Page | Contact CDER | What's New @ CDER
FDA Home Page | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page
FDA/Center for Drug Evaluation and Research
Office of Training and Communications
Division of Information Services
Update Frequency: Daily